The article discusses gene therapy, focusing on the development of the technique after setbacks in the 1990s and potential approval of treatments in the U.S. as of March 2014. Topics include the death of gene therapy patient Jesse Gelsinger from immune system response to the adenovirus used to deliver the genes, research into alternative delivery mechanisms including the adeno-associated virus (AAV) and HIV, and use in treating non-hereditary diseases.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados